Letter: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65).
作者信息
Oh Jee-Young
机构信息
Department of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea.
出版信息
Diabetes Metab J. 2011 Jun;35(3):298-9. doi: 10.4093/dmj.2011.35.3.298. Epub 2011 Jun 30.
Abstract
摘要
相似文献
1
Letter: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65).信函：西他列汀治疗韩国2型糖尿病疗效的预测性临床参数（《糖尿病与代谢杂志》2011年；35:159 - 165）
Diabetes Metab J. 2011 Jun;35(3):298-9. doi: 10.4093/dmj.2011.35.3.298. Epub 2011 Jun 30.
2
Response: predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus (diabetes metab j 2011;35:159-65).反应：西他列汀治疗韩国2型糖尿病疗效的预测临床参数（《糖尿病与代谢杂志》2011年；35:159 - 165）
Diabetes Metab J. 2011 Jun;35(3):300-1. doi: 10.4093/dmj.2011.35.3.300. Epub 2011 Jun 30.
3
Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.预测西他列汀治疗韩国 2 型糖尿病疗效的临床参数。
Diabetes Metab J. 2011 Apr;35(2):159-65. doi: 10.4093/dmj.2011.35.2.159. Epub 2011 Apr 30.
4
Letter: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30).信函：中等强度他汀类药物对韩国2型糖尿病患者血脂异常的治疗效果（《糖尿病代谢杂志》2017年；第41卷：第23 - 30页）
Diabetes Metab J. 2017 Apr;41(2):150-151. doi: 10.4093/dmj.2017.41.2.150.
5
Letter: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404).信函：基于标准化临床数据的韩国长期2型糖尿病视网膜病变患者的特征：一项研究（《糖尿病代谢杂志》2017年；41:393 - 404）
Diabetes Metab J. 2017 Dec;41(6):492-493. doi: 10.4093/dmj.2017.41.6.492.
6
Letter: the prevalence of peripheral arterial disease in korean patients with type 2 diabetes mellitus attending a university hospital (diabetes metab j 2011;35:543-50).信函：大学医院中2型糖尿病韩国患者外周动脉疾病的患病率（《糖尿病与代谢杂志》2011年；35:543 - 50）
Diabetes Metab J. 2011 Dec;35(6):637-9. doi: 10.4093/dmj.2011.35.6.637. Epub 2011 Dec 26.
7
Letter: Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2015;39:342-7).信函：2型糖尿病患者中双肽基肽酶-4抑制剂疗效的预测因素（《糖尿病代谢杂志》2015年；39:342 - 347）
Diabetes Metab J. 2015 Oct;39(5):444-5. doi: 10.4093/dmj.2015.39.5.444. Epub 2015 Oct 22.
8
Letter: genome-wide association study identifies two novel Loci with sex-specific effects for type 2 diabetes mellitus and glycemic traits in a korean population (diabetes metab j 2014;38:375-87).信函：全基因组关联研究在韩国人群中鉴定出两个对2型糖尿病和血糖性状具有性别特异性效应的新基因座（《糖尿病与代谢杂志》2014年；38:375 - 87）
Diabetes Metab J. 2014 Dec;38(6):484-6. doi: 10.4093/dmj.2014.38.6.484.
9
Letter: Associations among Obesity Degree, Glycemic Status, and Risk of Heart Failure in 9,720,220 Korean Adults (Diabetes Metab J 2020;44:592-601).信函：9720220名韩国成年人的肥胖程度、血糖状态与心力衰竭风险之间的关联（《糖尿病代谢杂志》2020年；44：592 - 601）
Diabetes Metab J. 2020 Oct;44(5):777-778. doi: 10.4093/dmj.2020.0202. Epub 2020 Oct 21.
10
Response: Efficacy of Moderate Intensity Statins in the Treatment of Dyslipidemia in Korean Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2017;41:23-30).回应：中等强度他汀类药物治疗韩国2型糖尿病患者血脂异常的疗效（《糖尿病代谢杂志》2017年；41:23 - 30）
Diabetes Metab J. 2017 Apr;41(2):152-153. doi: 10.4093/dmj.2017.41.2.152.
本文引用的文献
1
Predictive clinical parameters for the therapeutic efficacy of sitagliptin in korean type 2 diabetes mellitus.预测西他列汀治疗韩国 2 型糖尿病疗效的临床参数。
Diabetes Metab J. 2011 Apr;35(2):159-65. doi: 10.4093/dmj.2011.35.2.159. Epub 2011 Apr 30.
2
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.西格列汀在中国、印度和韩国2型糖尿病患者治疗中的疗效与安全性。
Diabetes Res Clin Pract. 2009 Jan;83(1):106-16. doi: 10.1016/j.diabres.2008.10.009. Epub 2008 Dec 20.
3
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.肠促胰岛素疗法治疗2型糖尿病的疗效与安全性：系统评价与荟萃分析
JAMA. 2007 Jul 11;298(2):194-206. doi: 10.1001/jama.298.2.194.
4
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.在仅使用二甲双胍血糖控制不佳的2型糖尿病患者中，二肽基肽酶-4抑制剂西他列汀与磺脲类药物格列吡嗪相比的疗效和安全性：一项随机、双盲、非劣效性试验。
Diabetes Obes Metab. 2007 Mar;9(2):194-205. doi: 10.1111/j.1463-1326.2006.00704.x.
5
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.在仅使用二甲双胍治疗血糖控制不佳的2型糖尿病患者中，加用二肽基肽酶-4抑制剂西他列汀的疗效和安全性。
Diabetes Care. 2006 Dec;29(12):2638-43. doi: 10.2337/dc06-0706.
6
Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.二肽基肽酶-4抑制剂西他列汀单药治疗对2型糖尿病患者血糖控制的影响。
Diabetes Care. 2006 Dec;29(12):2632-7. doi: 10.2337/dc06-0703.
7
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.肠促胰岛素系统：2型糖尿病中的胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂
Lancet. 2006 Nov 11;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5.
8
Epidemic obesity and type 2 diabetes in Asia.亚洲的流行性肥胖与2型糖尿病。
Lancet. 2006 Nov 11;368(9548):1681-8. doi: 10.1016/S0140-6736(06)69703-1.
9
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.二肽基肽酶-4抑制剂西他列汀作为2型糖尿病患者单药治疗的疗效与安全性
Diabetologia. 2006 Nov;49(11):2564-71. doi: 10.1007/s00125-006-0416-z. Epub 2006 Sep 26.
10
Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.肠促胰岛素激素在糖尿病和非糖尿病患者胰岛素分泌调节中的作用。
Am J Physiol Endocrinol Metab. 2004 Aug;287(2):E199-206. doi: 10.1152/ajpendo.00545.2003.
Zotero 插件